Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Expenses (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Operating Expenses data on record, last reported at $251.1 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 5.18% year-over-year to $251.1 million; the TTM value through Dec 2025 reached $948.4 million, changed 0.21%, while the annual FY2025 figure was $948.4 million, 0.21% changed from the prior year.
  • Operating Expenses reached $251.1 million in Q4 2025 per APLS's latest filing, up from $235.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $251.1 million in Q4 2025 and bottomed at $124.6 million in Q1 2021.
  • Average Operating Expenses over 5 years is $204.1 million, with a median of $217.7 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: surged 68.74% in 2021, then fell 15.37% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $149.7 million in 2021, then increased by 24.73% to $186.7 million in 2022, then grew by 23.66% to $230.9 million in 2023, then grew by 3.38% to $238.7 million in 2024, then rose by 5.18% to $251.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $251.1 million in Q4 2025, $235.4 million in Q3 2025, and $211.8 million in Q2 2025.